| 000 | 01504 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513091132.0 | ||
| 264 | 0 | _c19960712 | |
| 008 | 199607s 0 0 eng d | ||
| 022 | _a0090-8258 | ||
| 024 | 7 |
_a10.1006/gyno.1996.0154 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMangili, G | |
| 245 | 0 | 0 |
_aOctreotide in the management of bowel obstruction in terminal ovarian cancer. _h[electronic resource] |
| 260 |
_bGynecologic oncology _cJun 1996 |
||
| 300 |
_a345-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma _xcomplications |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGastrointestinal Agents _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIntestinal Obstruction _xcomplications |
| 650 | 0 | 4 | _aIntubation, Gastrointestinal |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOctreotide _xtherapeutic use |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xcomplications |
| 650 | 0 | 4 | _aPalliative Care |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVomiting _xetiology |
| 700 | 1 | _aFranchi, M | |
| 700 | 1 | _aMariani, A | |
| 700 | 1 | _aZanaboni, F | |
| 700 | 1 | _aRabaiotti, E | |
| 700 | 1 | _aFrigerio, L | |
| 700 | 1 | _aBolis, P F | |
| 700 | 1 | _aFerrari, A | |
| 773 | 0 |
_tGynecologic oncology _gvol. 61 _gno. 3 _gp. 345-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1006/gyno.1996.0154 _zAvailable from publisher's website |
| 999 |
_c8640649 _d8640649 |
||